**Priority Report**

**5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations**

Seung-Gi Jin, Yong Jiang, Runxiang Qiu, Tibor A. Rauch, Yinsheng Wang, Gabriele Schackert, Dietmar Krex, Qiang Lu, and Gerd P. Pfeifer

**Abstract**

The base 5-hydroxymethylcytosine (5hmC) was recently identified as an oxidation product of 5-methylcytosine in mammalian DNA. Here, using sensitive and quantitative methods to assess levels of 5-hydroxymethyl-2'-deoxycytidine (5hmC) and 5-methyl-2'-deoxycytidine (5mC) in genomic DNA, we investigated whether levels of 5hmC can distinguish normal tissue from tumor tissue. In squamous cell lung cancers, levels of 5hmC were depleted substantially with up to 5-fold reduction compared with normal lung tissue. In brain tumors, 5hmC showed an even more drastic reduction with levels up to more than 30-fold lower than in normal brain, but 5mC levels were independent of mutations in isocitrate dehydrogenase-1. Furthermore, immunohistochemical analysis indicated that 5hmC is remarkably depleted in many types of human cancer. Importantly, an inverse relationship between 5hmC levels and cell proliferation was observed with lack of 5hmC in proliferating cells. The data therefore suggest that 5hmC is strongly depleted in human malignant tumors, a finding that adds another layer of complexity to the aberrant epigenome found in cancer tissue. In addition, a lack of 5hmC may become a useful biomarker for cancer diagnosis. *Cancer Res; 71(24); 7360–5. ©2011 AACR.*

**Introduction**

Recently, 5-hydroxymethylcytosine (5hmC) has been identified as an oxidation product of 5-methylcytosine in mammalian DNA (1, 2) generated by the α-ketoglutarate–dependent Tet dioxygenases (2, 3). Levels of 5hmC are tissue dependent and the highest levels have been found in the central nervous system (4, 5). The biological function of 5hmC is currently unknown. 5hmC may be an intermediate in DNA demethylation processes that accomplishes the conversion of 5mC to cytosine (6). The distribution of 5hmC in embryonic stem cells (7–12), mouse cerebellum (13), and human prefrontal cortex (14) has been mapped by array- or sequencing-based assays. 5hmC was enriched at promoters and within gene bodies.

Several hematologic malignancies carry mutations in one of the TET genes, *TET2* (15). *TET2* mutations were linked to aberrant levels of 5hmC and 5mC in these cancer genomes (16, 17). Also, mutations in isocitrate dehydrogenase-1 (IDH1) have been linked to abnormal DNA methylation patterns (18). One attractive proposal is that mutated IDH1 produces a new metabolite, 2-hydroxyglutarate (2HG; ref. 19), which can inhibit TET proteins potentially leading to altered levels of 5hmC and 5mC in tumors (20).

Systematic studies on levels of 5hmC in human cancers are lacking. Here, we have used liquid chromatography/tandem mass spectrometry (LC/MS-MS), to assess the levels of 5-hydroxymethyl-2'-deoxycytidine (5hmC) and 5-methyl-2'-deoxycytidine (5mC) in human lung carcinomas and in brain tumor DNA. We also used immunofluorescence staining to assess 5hmC in a series of normal and malignant tissue sections.

**Materials and Methods**

**DNA samples**

Stage-I lung squamous cell carcinoma (SCC) and adenocarcinoma samples and matched normal tissues were obtained from the frozen tumor bank of the City of Hope Medical Center under an Institutional Review Board approved protocol. Samples were obtained from tumors without laser-capture microdissection. DNA from primary small cell lung cancers and matched normal lung was obtained from Asterand, BioChain, and Cureline. Normal human brain tissue DNAs of the prefrontal cortex were obtained from Capital Biosciences and BioChain. DNA from neurons and astrocytes of fetal (24 weeks of gestation) human brain was obtained from ScienCell.

---

Authors' Affiliations: Departments of 1Cancer Biology and 2Neurosciences, Beckman Research Institute of the City of Hope, Duarte; 3Department of Chemistry, University of California Riverside, Riverside, California; 4Department of Orthopedic Surgery, Section of Molecular Medicine, Rush University Medical Center, Chicago, Illinois; and 5Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

S.-G. Jin, Y. Jiang, and R. Qiu contributed equally to the work.

Corresponding Author: Gerd P. Pfeifer, Department of Cancer Biology, Beckman Research Institute, City of Hope, 1500 E. Duarte Road, Duarte, CA 91010. Phone: 626-301-8853; Fax: 626-358-7703; E-mail: gpfeifer@coh.org

doi: 10.1158/0008-5472.CAN-11-2023

©2011 American Association for Cancer Research.
Twenty-seven astrocytomas (World Health Organization, grade II–III) were obtained on Institutional Review Board approved protocols at the Department of Neurosurgery at the University Hospital in Dresden. DNA was isolated by standard procedures with phenol-chloroform extraction and ethanol precipitation. Eight additional brain tumor DNAs were obtained from Asterand. Genomic DNAs from tissues and cell lines were isolated by the help of the DNeasy Tissue Kit (QIAGEN).

**IDH mutations**

For sequencing of IDH1 and IDH2 exon 4, 4.40 ng of genomic DNA was used for PCR amplification using the following primers: for IDH1, forward 5'-TGCCACACGACGACATCG and reverse 5'-CATGAATCTCATATTTGCC, for IDH2, forward 5'-GGAAGATGCGGCTGAGT and reverse 5'-GGGGTGAGACATTTTGA.

**Simultaneous quantification of 5mdC and 5hmC by LC/MS-MS**

Genomic DNA (1–2 µg) was incubated with 5 units of DNA Degradase Plus (Zymo Research) at 37°C for at least 2 hours. The stable isotope labeled 5hmC (21, 22) and labeled 2'-deoxyguanosine (Cambridge Isotope Laboratories) were added as internal standards. Aliquots of the mixture were subjected directly to LC/MS-MS analysis. LC/MS-MS was carried out with a Thermo Accela 600 HPLC pump interfaced with a TSQ Vantage triple stage quadruple mass spectrometer (Thermo Fisher Scientific). A 2.1 x 50 mm Kinetex XB-C18 column (2.6 µm in particle size and 100 Å in pore size; Phenomenex) was used for separation at a flow rate of 400 µL/min. The TSQ mass spectrometer was optimized and set up in selected reaction monitoring scan mode for monitoring the [M + H]+ ions of 5hmC (m/z 258.1 → 142.1), 5mdC (m/z 242.1 → 126.1), dG (m/z 268.1 → 152.1), labeled 5hmC (m/z 261.1 → 144.1) and labeled dG (m/z 273.1 → 157.1). Thermo Xcalibur software (version 2.1) was used to conduct data analysis.

Immunodot blot analysis for 5hmC was conducted as described previously (14).

**Immunohistochemistry**

Frozen tissue arrays were from Biochain (catalog no. T6235700-5 and lot no. B403109). They contain normal brain tissue and craniopharyngioma, normal breast and invasive ductal carcinoma, normal colon and adenocarcinoma, normal skeletal muscle and rhabdomyosarcoma, normal kidney and renal cell carcinoma, normal liver and hepatocellular carcinoma, normal lung and SCC, normal pancreas and adenocarcinoma, normal prostate and adenocarcinoma, normal skin and malignant melanoma, normal small intestine and malignant mesenchymoma, normal stomach and adenocarcinoma, normal uterus and adenocarcinoma, and normal ovary and cystadenocarcinoma. The tissue sections were boiled in 10 mmol/L sodium citrate for antigen retrieval followed by blocking with 10% goat serum, 0.1% Triton X-100 in PBS for 1 hour at room temperature (RT). Sections were incubated with primary anti-5hmC polyclonal antibody (dilution 1:1,000; Active Motif) in 5% goat serum, 0.01% Triton X-100 in PBS at 4°C, overnight. After washing with PBS at RT, sections were incubated with Rhod Red-X-AfniPure conjugated goat anti-rabbit secondary antibody (dilution 1:200; Jackson ImmunoResearch) for 1 hour at RT, then washed with PBS and water, and mounted with fluoromount-G solution (SouthernBiotech). Ki67 staining was carried out with Ki67 antibody (BD Pharmingen; catalog no. 550846).

Figure 1. Quantitation of 5hmC and 5mdC in normal lung and lung SCC DNA. A, 5hmC. The first 18 samples are matched normal lung (LN, blue) and lung tumors (LT, green). The last 8 samples are lung tumors without available normal tissue. B, 5mdC. The asterisks (*) indicate that the levels of 5mdC were significantly reduced in the tumor compared with normal lung (P < 0.05).
number 550609; dilution 1:20). The anti-5mC antibody was from Eurogentec (catalog no. BI-MECY-0100; dilution 1:200). Slides were counterstained with Hoechst 33258 dye. All fluorescent images were taken with an inverted Olympus IX 81 fluorescence microscope.

**Reverse transcriptase PCR**

Quantitative reverse transcriptase PCR was carried out as described (23).

**Results and Discussion**

To determine the levels of 5hmC and 5mC in normal and tumor tissues, we developed a sensitive LC/MS-MS assay with isotope-labeled internal standards (Supplementary Fig. S1A). 5mC was quantitated with reference to the dG standard. Supplementary Fig. S1B shows examples of LC separation and how mass spectrometric analysis of 5hmC and 5mC was achieved. The method is strictly quantitative as shown by standard curves (Supplementary Fig. S2). We initially tested its performance by measuring 5hmC and 5mC in several cell and tissue DNA samples (Supplementary Fig. S3). The data obtained were consistent with values reported in the literature (2, 4) and were also generally in agreement with a less quantitative immunodot blot assay (Supplementary Fig. S4).

Using the LC/MS-MS assay, we measured 5hmC in 24 stage-I lung SCC DNAs and in matched normal lung DNA (Fig. 1A). The levels of 5hmC, expressed as percentage of dG, were between 0.078% and 0.182% in normal lung. In every SCC tumor except one (LT2), we saw a significant reduction of 5hmC level compared with the paired normal lung sample ($P<0.05$ for each sample pair; $t$ test; Fig. 1A). 5hmC levels were generally 2- to 5-fold lower in the tumors than in normal lung ($P = 8.88 \times 10^{-7}$; paired $t$ test). We also quantitated 5mC (Fig. 1B). 5mC was depleted in most tumor samples with a few exceptions (tumors 1, 2, 6, 7, 15, and 16). In many cases, 5mC levels were lower by only approximately 5% to 20% ($P = 0.023$; paired $t$ test). $IDH1$ or $IDH2$ mutations were not found in these lung tumors. We also analyzed 5mC in lung adenocarcinomas and primary small cell lung cancers (Supplementary Fig. S5). As with SCC, 5mC was depleted in most of these tumors relative to matched normal tissue.

Next, we analyzed the 2 modified 2’-deoxynucleosides in 6 normal brain DNA samples and in 33 stage II and III astrocytomas (astrocytic gliomas) and in 2 glioblastomas. We found high levels of 5hmC in normal human brain prefrontal cortex DNA (Fig. 2A), in which 5hmC was between 0.82% and 1.18% of dG. We also measured levels of 5hmC and 5mC in astrocytes and in neurons from human fetal brain. Levels of 5hmC were higher (1.45% 5hmC/dG) in neurons than in astrocytes (0.23% 5hmC/dG; Supplementary Fig. S6). In brain tumors, 5hmC was strongly depleted relative to normal brain (Fig. 2A). Some astrocytomas contained only 0.03% to 0.04% of 5hmC, a reduction of more than 30-fold ($P = 1.55 \times 10^{-11}$; unpaired $t$ test). Because astrocytomas initiate in neural stem cells or glial progenitor cells, their decreased level of 5hmC may be due to either the malignant state or to the cell of origin of these tumors. The varying levels of 5hmC in tumors did not

![Figure 2. Quantitation of 5hmC and 5mC in normal brain DNA and in stage II/III astrocytomas. A, 5hmC quantitation in normal brain (BN, blue) and in brain tumors (BT, green or orange). Samples BT1–16, BT25, BT27–29, and BT32-36 were stage III astrocytomas; BT17-24, BT26, BT30, and BT31 were stage II astrocytomas; and BT37 and BT38 were glioblastomas. B, 5mC in BN and in BTs. Tumors with no IDH1 mutation are shown in green; tumors with IDH1 R132H are shown in orange. The sample BT26 had a minor allele frequency of IDH1 R132H. Sample BT25 had the rare mutation R132G.](image-url)
to correlate with patient age or whether the tumor was stage II or III or with patient survival (data not shown). Levels of 5mC showed only a small reduction in some brain tumors (Fig. 2B; \( P = 0.3 \); unpaired \( t \) test). There was no correlation between levels of 5hmC and levels of 5mC. A substantial fraction of stages II and III gliomas contain mutations in \( IDH1 \) and much more rarely, in \( IDH2 \) (24). We determined the mutation status of \( IDH1 \) at codon 132 (Supplementary Fig. S7). We identified 16 stage II/III tumors with the typical codon R132H mutation, and 17 stage II/III tumors without any \( IDH1 \) mutation. The R132H \( IDH1 \) mutation produces a neomorphic enzyme with the capacity to generate 2HG (19). We expected that IDH1-mutant tumors would have lower levels of 5hmC according to the presumed role of 2HG as an inhibitor of TET oxidases (see Supplementary Fig. S8). Surprisingly, however, the levels of 5hmC were evenly distributed between the low and high ranges, both in IDH1 wild type and in IDH1-mutant tumors (Fig. 2A; \( P = 0.53 \); \( t \) test, nonpaired). This finding is in contrast to a previous report, which observed a significant reduction of 5hmC in IDH1-mutant gliomas by immunohistochemistry (20). Similarly, IDH1-mutant and wild-type cases did not show differences in levels of 5mC (Fig. 2B).

To investigate whether loss of 5hmC is a feature of human cancers in general, we conducted immunohistochemical staining with an anti-5hmC antibody (Fig. 3 and Supplementary Fig. S9). This antibody was verified previously by us and used for detecting 5hmC in early embryos (14, 23). Normal tissue sections and corresponding tumor were stained with this antibody. We observed substantial 5hmC staining of almost all cells in most normal tissues. However, staining in corresponding tumors was universally decreased with only a few cells (<10%) staining positive for 5hmC. The only exception was a tumor originating in the colon (Supplementary Fig. S9). Additional lung tumor slides were also analyzed (Supplementary Fig. S10) including tumor and adjacent normal lung (Supplementary Fig. S10A).

We also did parallel staining of several normal and tumor sections for 5mC using an anti-5mC antibody (Supplementary Fig. S11) and did not observe a substantial decrease of 5mC staining in the tumors. This means that the loss of 5hmC is not simply due to loss of 5mC in tumors. We then determined whether reduced staining of 5hmC in tumors is due to increased cell proliferation. We used an anti-Ki67 antibody to stain proliferating cells. Sections of normal brain were almost

![Figure 3. Immunohistochemical analysis of 5hmC on human tissue arrays.](https://cancerres.aacrjournals.org)
completely devoid of Ki67 antigen but brain tumors contained many Ki67-positive cells that lacked 5hmC staining (Supplementary Fig. S12). Similarly, there was little Ki67 staining in normal lung, but in adjacent carcinoma tissue, we saw mutually exclusive staining of Ki67 and 5hmC (Fig. 4 and Supplementary Fig. S10). The same was found for sections of breast, pancreatic tumors, and uterus tumors (Supplementary Fig. S13). Tissue sections of normal small intestine showed strong Ki67 staining for proliferating cells at the bottom of crypts with lack of 5hmC staining, whereas the more differentiated cells contained high levels of 5hmC and lacked Ki67 staining (Fig. 4). Thus, one straightforward explanation for the loss of 5hmdC in tumors is the enhanced rate of cell proliferation in tumors that could lead to a passive loss of 5hmdC, which is not a substrate for DNA methyltransferase 1 (25). We noticed that not all cells that lack 5hmC staining in the tumors are Ki67 positive perhaps due to past history of proliferation leading to permanent loss of 5hmC.

The inverse link between 5hmC levels and cell proliferation may also reflect intrinsic differences in cell type, as we are comparing differentiated cells with undifferentiated cancer cells that carry stem cell–like properties or originate from somatic stem cells. Another alternative is the possible existence of aberrations in 5hmC production or elimination pathways in tumors. Mutations in TET genes have not been reported in solid tumors. With the exception of TET3 in brain, there was no substantial reduction of TET gene expression in lung and brain tumors relative to normal tissue as confirmed by reverse transcriptase PCR (Supplementary Fig. S14).

The loss of 5hmdC in tumors may have profound effects on DNA methylation patterns. For example, if 5hmC is an intermediate in DNA demethylation, its loss at specific genomic locations may make these sequences more prone to acquire methylation. It will be essential to understand the mechanisms of how 5hmC is lost in tumors. Finally, loss of 5hmC could become a useful molecular biomarker for cancer detection and diagnosis, perhaps in conjunction with Ki67 staining.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported by NIH grants CA084469 and AG036041 to G.P. Pfeifer, NS075393 to Q. Lu, and CA101864 to Y. Wang.

Received June 16, 2011; revised September 20, 2011; accepted October 3, 2011; published OnlineFirst November 3, 2011.
References

5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations

Seung-Gi Jin, Yong Jiang, Runxiang Qiu, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-2023

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2011/11/03/0008-5472.CAN-11-2023.DC1

Cited articles
This article cites 25 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/71/24/7360.full.html#ref-list-1

Citing articles
This article has been cited by 26 HighWire-hosted articles. Access the articles at:
/content/71/24/7360.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.